Every day researchers work towards finding new breakthroughs in cancer. Clinical trials play a pivotal role in bringing that defeat closer.
Clinical trials test promising new treatments on people to see if they are better than existing cancer treatments. The trial process is long starting many years before an actual treatment can be used.
By joining a clinical trial you are helping to create new breakthroughs in cancer research. Hundreds of thousands of people all over the world have taken part in clinical trials that have lead to safer and more effective treatments for many cancers.
It is important to note that not all cancer patients are eligible to take part in clinical trials and there are not clinical trials for all types of cancer.
You may decide to join a clinical trial because:
- The treatment you receive will be at least the best available for your illness.
- Your health may improve because of the treatment you receive.
- You may receive a treatment you would not otherwise have access to.
- Your health will be carefully checked by the treatment team running the trial.
- You will be part of the worldwide effort to improve cancer treatment.
For more information on clinical trials please click here.
If you would like information regarding any of the below clinical trials, please contact the appropriate Clinical trials manager:
Ashford Cancer Centre: Helen Daykin, +61 8 8292 2240
Flinders Medical Centre: Alex Scott-Hoy, +61 8 8204 4830
The Queen Elizabeth: Sue Yeend, +61 8 8222 6148
Lyell McEwin Hospitals: Julie Rowe or Rohit Joshi +61 8 8282 0833
Royal Adelaide Hospital: Anne Milton, +61 8 7074 2342
Current clinical trials for lymphoma cancer
|Recruiting||BAY 80-6946 / 17833 CHRONOS 4 A Phase III, randomized, double-blind, controlled, multicentre study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL)||Ashford Cancer Centre Research|
|Not yet recruiting||BGB-3100-GA101 A Phase 1b Study to Assess Safety, Tolerability and Antitumor Activity of the Combination of BGB-3111 with Obinutuzumab in Subjects with B-Cell Lymphoid Malignancies||Ashford Cancer Centre Research|
|Recruiting||Harmony B029563. A Phase Ib/II Study Evaluating the Safety and Efficacy of MPDL3280A in combination with either Obinutuzumab plus bendamustine or Obinutuzumab plus chop in patients with follicular lymphoma or diffuse large B-cell lymphoma||The Queen Elizabeth Hospital|
|Recruiting||Harmony-GO29833 A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination with Polatuzumab Vedotin and Venetoclax in Patients with Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma||The Queen Elizabeth Hospital|